Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150107 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes
A Phase 2 study, sponsored by Oramed.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04150107 is a Phase 2 study that has completed, run by Oramed. The registered enrollment target is 30 participants.
The verdict
NCT04150107, a Phase 2 study, has completed, sponsored by Oramed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collected. Vital signs will be measured, physical exam will be performed, and blood and urine samples will be collected for hematology/chemistry/urinalysis Placebo capsules will be given QD at bedtime during placebo run-in period 10 days prior to randomization.
Interventions
- OTHER Placebo
- DRUG ORMD-0801 Treatment A
- DRUG ORMD-0801 Treatment B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2020-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150107
The ClinicalTrials.gov registry entry for NCT04150107 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oramed, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04150107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04150107 about?
NCT04150107 is a clinical study titled "A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes". This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collecte...
What is the current status of trial NCT04150107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-17. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT04150107?
The interventions under investigation include: Placebo (OTHER), ORMD-0801 Treatment A (DRUG), ORMD-0801 Treatment B (DRUG).
Who is sponsoring clinical trial NCT04150107?
This trial is sponsored by Oramed, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.